XM does not provide services to residents of the United States of America.

Abu Dhabi's ADNOC to buy German chemicals company Covestro for $18 bln



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 3-Abu Dhabi's ADNOC to buy German chemicals company Covestro for $18 bln</title></head><body>

ADNOC to pay 62 euros a Covestro share, including 3 bln in debt

To buy additional 1.2 bln euros worth of new shares in Covestro

Covestro shares jump 3.7% to a three-year high

Deal could fuel debate of foreign takeovers of German companies

Adds shares in paragraph 5, capital threshold in paragraph 9, background on Germany from paragraph 10

By Ludwig Burger

BERLIN, Oct 1 (Reuters) -Abu Dhabi's ADNOC has agreed to buy German chemicals producer Covestro 1COV.DE for 15.9 billion euros ($18 billion) including debt, the state oil giant said on Tuesday, representing its largest acquisition to date.

The deal is one of the biggest foreign takeovers by a Gulf state as Abu Dhabi and other countries in the region seek to reduce their economies' heavy dependence on oil in the face of the global energy transition.

It follows protracted negotiations between the two companies and will see ADNOC pay 62 euros per Covestro share, equal to 14.7 billion euros including about 3 billion euros in debt.

ADNOC added it would also buy 1.17 billion euros worth of new shares in Covestro, a former Bayer BAYGn.DE unit, from a capital increase to improve funding of the takeover target.

Covestro shares jumped 3.7% to a three-year high of 58 euros.

The deal is a cornerstone for ADNOC's plans to grow its petrochemicals business along with gas and renewable energy.

ADNOC has also been in talks with Austria's OMV for more than a year to merge their petrochemical joint ventures Borealis and Borouge. ADNOC took a 24.9% stake in OMV from Abu Dhabi sovereign fund Mubadala in February.

Covestro, which makes plastics and chemicals for the automotive, construction and engineering sectors, was created in 2015 after being spun off from Bayer. It opened its books to ADNOC in June - a year after ADNOC's initial interest was reported.

The public takeover offer will be subject to a minimum acceptance threshold of 50% plus one share of Covestro's capital.


WIDE-RANGING CONCESSIONS

The deal could reignite a debate about Germany's blue-chip companies facing foreign takeover overtures because of a weak economy.

Italy's UniCredit CRDI.MI is seeking to merge with Commerzbank CBKG.DE after snapping up a stake in its German rival, drawing criticism from Germany's political establishment, who want to keep the lender independent.

Covestro, however, said it won wide-ranging concessions to limit the buyer's control of the company.

Half of the seats on its supervisory board would continue to be held by labour representatives, as is the norm at German listed companies, and two members of the board's shareholder representatives will remain independent of ADNOC.

ADNOC pledged not to sell, close or significantly reduce Covestro's business activities and it would "protect Covestro's technology and intellectual property", Covestro said.

It added that its management board would stay in charge of management and strategic direction.

Covestro reported a net loss of 72 million euros in the first six months of the year, compared with 46 million euros profit in the previous year.

The agreement illustrates an increase in dealmaking between the Middle East and Europe, as Gulf investors are drawn to company valuations that lag those in the United States, an easier regulatory backdrop for buyers from the region, and where investment needs make them more welcome, advisers and analysts have told Reuters.

It is the Middle East's second biggest acquisition after Israel's Teva Pharmaceuticals' acquisition of Allergan's generic drugs business for around $40 billion in 2015, according to Dealogic data.


($1 = 0.8990 euros)



Reporting by Ludwig Burger
Additional reporting by Friederike Heine
Editing by David Goodman and Emelia Sithole-Matarise

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.